Post a Free Blog

Submit A Press Release

At CWEB, we are always looking to expand our network of strategic investors and partners. If you're interested in exploring investment opportunities or discussing potential partnerships and serious inquiries. Contact: jacque@cweb.com

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessPrecision BioSciences, Inc. (NASDAQ:DTIL) Earnings Report Analysis

Precision BioSciences, Inc. (NASDAQ:DTIL) Earnings Report Analysis

Add to Favorite
Added to Favorite


Earnings per Share (EPS) of -$2.735 was below the estimated EPS of -$2.09.
DTIL’s debt-to-equity ratio is 0.47, suggesting a moderate level of debt relative to equity.

Precision BioSciences, Inc. (NASDAQ:DTIL) is a clinical-stage gene editing company that focuses on developing in vivo gene editing therapies using its proprietary ARCUS® platform. On March 26, 2025, DTIL reported an earnings per share (EPS) of -$2.735, which was below the estimated EPS of -$2.09. The company’s actual revenue was $3.471 million, falling short of the estimated revenue of $4.275 million.
DTIL’s price-to-sales ratio is 0.53, which means the market values the company’s sales at just over half of its current market price. This could imply that investors are cautious about the company’s ability to generate revenue in the future. Additionally, the enterprise value to sales ratio is negative at -0.38, indicating that the company’s liabilities exceed its market capitalization and cash.
The enterprise value to operating cash flow ratio is 0.59, reflecting the company’s ability to generate cash relative to its enterprise value. This suggests that DTIL is relatively efficient in generating cash from its operations. 
DTIL’s debt-to-equity ratio is 0.47, indicating a moderate level of debt relative to equity. This suggests that the company is not overly reliant on debt to finance its operations. Additionally, DTIL has a strong current ratio of 9.22, suggesting a robust ability to cover its short-term liabilities with its short-term assets.

Subscribe to get Latest News Updates

Latest News

You may like more
more